Major US research university serving as a transatlantic third-party host across biomedical, sensing, energy, and humanities projects in H2020.
The University of Michigan is a major US research university that participates in European research primarily as a third-party host and partner for researcher mobility under Marie Skłodowska-Curie Actions. Its H2020 involvement spans an unusually wide range of disciplines — from diabetic kidney disease biomarkers and hospital-acquired pneumonia immunotherapy to chemical threat sensing, space weather prediction, and digital archaeology. Rather than contributing deep expertise in one domain, UMich serves as a world-class research environment where European fellows and collaborative networks access specialized labs, clinical infrastructure, and interdisciplinary faculty across medicine, engineering, humanities, and social sciences.
BEAt-DKD (diabetic kidney disease biomarkers), HAP2 (hospital-acquired pneumonia immunotherapy), DRIVE (autophagy), and MUC (gut microbiome in ulcerative colitis) demonstrate sustained biomedical involvement.
PROGRESS and PAGER both focus on predicting geomagnetic storms and radiation effects on satellites and infrastructure.
SENSOFT addresses rapid-response chemical threat detection using smart sensor networks, nanomaterials, and SERS on flexible substrates.
NEFERTITI explores photocatalytic CO2/H2O conversion to solar ethanol using flow reactor systems.
ENART (Islamic aesthetics), MOBILESITES (Ottoman holy site representations), HARMONI (legal history), MOCC (campus microaggressions), and PleasDef span cultural, legal, and social research.
In the early period (2015–2018), UMich's H2020 work centered on life sciences and biomedical research — diabetic kidney disease, autophagy biomarkers, gut microbiome, and drug delivery systems. From 2019 onward, the profile diversified sharply into security-oriented sensing (chemical threat detection), energy (photocatalysis), and a growing cluster of humanities and social science fellowships. This shift reflects the university's breadth rather than a strategic pivot: as more MSCA fellows chose UMich as a host, the topical range expanded well beyond its initial biomedical core.
UMich is increasingly attracting MSCA fellows in applied technology domains (sensors, photocatalysis) alongside its traditional biomedical strengths, suggesting growing value as a transatlantic bridge for engineering-oriented collaborations.
UMich has never coordinated an H2020 project — it participates exclusively as a partner or third-party contributor, which is typical for non-EU institutions that cannot lead EU-funded consortia. With 15 of its 21 involvements as a third party (associated partner), it typically provides specialized research capacity to European-led networks rather than driving project design. Its 155 unique partners across 30 countries indicate a broad, non-exclusive network: many different European groups choose UMich as a transatlantic partner, but the relationships tend to be project-specific rather than repeated.
Extensive network of 155 unique partners spanning 30 countries, reflecting UMich's role as a go-to US-based host institution for European researcher mobility programs. The connections are wide but shallow — driven by individual MSCA fellows rather than deep institutional partnerships.
As one of the top US research universities, UMich offers European consortia something most partners cannot: access to American research infrastructure, clinical networks, and interdisciplinary faculty across dozens of departments. For MSCA applicants, it provides a prestigious transatlantic secondment host with proven experience in 21 H2020 projects. Its value lies not in narrow specialization but in the sheer depth and breadth of research capacity available under one institutional umbrella — from medical imaging to legal history to nanomaterial sensing.
